Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study.

Xiao-Feng ZengJu LiuXiumei LiuLijun WuYi LiuXiangping LiaoHuaxiang LiuJiankang HuXin LuLinjie ChenJian XuZhenyu JiangFu-Ai LuHuaxiang WuYing LiQingyu WangJun Zhunull null

Published in: Arthritis research & therapy (2022)

ClinicalTrials.gov , NCT03522415 . Registered on 11 May 2018.

Keyphrases

rheumatoid arthritis
open label
high dose
disease activity
high intensity
early onset
ankylosing spondylitis
randomized controlled trial
stem cells
double blind
low dose
placebo controlled
drug induced